Position in NVS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$212,169
-$99,003 QoQ
Shares Held
1,389
-38.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Roehl & Yi Investment Advisors, LLC holds $14,211,884 across 9 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
26,711 | $6,783,792 | |
| 2 | AMGN |
Amgen Inc
|
48,313 | $2,042,778 | |
| 3 | NVO |
Novo Nordisk A S
|
22,077 | $1,058,371 | |
| 4 | MRK |
Merck & Co., Inc.
|
7,486 | $961,951 | |
| 5 | ABBV |
AbbVie Inc.
|
3,171 | $797,950 | |
| 6 | PFE |
Pfizer Inc
|
31,305 | $753,824 | |
| 7 | LLY |
ELI LILLY & Co
|
626 | $750,843 | |
| 8 | AZN |
Astrazeneca PLC
|
3,863 | $732,502 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $212,169 | 1,389 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $311,172 | 2,257 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $351,377 | 2,740 | Shares | Sole | 2026-05-29 | |
| 2025-06-30 | $350,081 | 2,893 | Shares | Sole | 2026-05-29 | |
| 2025-03-31 | $322,511 | 2,893 | Shares | Sole | 2026-05-29 | |
| 2024-12-31 | $267,407 | 2,748 | Shares | Sole | 2026-05-29 | |
| No filing history on record for this holder in this stock. | ||||||